Anzeige
Mehr »
Montag, 08.09.2025 - Börsentäglich über 12.000 News
Tokenisierung entfesselt: Republic führt die Ethereum-Revolution
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AP4F | ISIN: CA7615161030 | Ticker-Symbol: 31R
Frankfurt
08.09.25 | 15:36
0,010 Euro
+900,00 % +0,009
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
REVIVE THERAPEUTICS LTD Chart 1 Jahr
5-Tage-Chart
REVIVE THERAPEUTICS LTD 5-Tage-Chart
RealtimeGeldBriefZeit
0,0080,01617:29

Aktuelle News zur REVIVE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07:30Revive Therapeutics announces extension of proposed private placement3
SaRevive Therapeutics Ltd: Revive extends $650,000 private placement1
SaRevive Therapeutics Ltd.: Revive Therapeutics Announces Extension of Proposed Private Placement5
12.08.Revive Therapeutics Ltd: Revive closes $60,900 first tranche of placement11
12.08.Revive Therapeutics Ltd.: Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement150TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing...
► Artikel lesen
REVIVE THERAPEUTICS Aktie jetzt für 0€ handeln
31.07.Revive Therapeutics Ltd: Revive Therapeutics arranges financing, debt settlement3
31.07.Revive Therapeutics Ltd.: Revive Therapeutics Announces Proposed Private Placement and Debt Settlement151TORONTO, July 30, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing...
► Artikel lesen
09.07.Revive Therapeutics Ltd: Revive has no future plans yet with Defence R&D4
08.07.Revive Therapeutics Ltd.: Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study1
26.06.Revive Therapeutics Ltd: Revive hopes to conclude bucillamine study by September7
04.06.Revive Therapeutics Ltd: Revive develops new bucillamine formulation6
04.06.Revive Therapeutics Ltd.: Revive Therapeutics Advances with Next-Generation Bucillamine Development14
13.05.Revive Therapeutics Ltd: Revive's bucillamine research study to end by June9
12.05.Revive Therapeutics Ltd.: Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure301TORONTO, May 12, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
► Artikel lesen
21.04.Revive Therapeutics Ltd: Revive Therapeutics to settle $150,000 debt with shares7
21.04.Revive Therapeutics announces proposed shares for debt transaction3
21.04.Revive Therapeutics Ltd.: Revive Therapeutics Announces Proposed Shares for Debt Transaction5
10.04.Revive Therapeutics Ltd: Revive to study bucillamine as cancer treatment6
10.04.Revive Therapeutics Ltd.: Revive Therapeutics to Investigate Bucillamine's Potential in Cancer Treatment355TORONTO, April 10, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. ("Revive" or the "Company") (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research...
► Artikel lesen
01.04.Revive Therapeutics Ltd: Revive agrees to buy Diagnamed's molecular hydrogen IP7
Weiter >>
25 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1